Alcohol use disorder treatment and outcomes among hospitalized adults with alcoholic hepatitis

Winters, Adam C.; May, Folasade P.; Wang, Yun; Shao, Paul; Yang, Liu; Patel, Arpan

doi:10.1016/j.dadr.2021.100004

Cited by 6 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alcoholic hepatitis is diagnosed among 10-35% of patients with alcohol dependence. Alcoholic hepatitis includes a wide range of nosologies from uncomplicated steatosis to liver cirrhosis caused by the systematic use of the psychoactive substance alcohol [8][9][10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Interdisciplinary Pharmacoeconomic Research Concerning the Рharmacotherapy of Alcoholic Hepatitis in Conditions of Covid-19 Pandemic

Шаповалова

2023

SSPMPM

View full text Add to dashboard Cite

Substantiated the relevance and necessity of the chosen research topic as a result of a review of the scientific literature on the epidemiology and pharmacotherapy of patients with alcoholic hepatitis. Contradictory evidence exists regarding the association between international and national clinical protocols for the management of alcoholic hepatitis in the context of the COVID-19 pandemic. Author undertook the present study to justify the procurement of drugs for patients with alcoholic hepatitis based on pharmacoeconomic calculations for hospitals. This study is based on pharmacoeconomic, organizational and legal, forensic and pharmaceutical approaches to pharmacotherapy with using literature review. Clinical and pharmacological analysis of basic therapy of alcoholic hepatitis was performed. Pharmacoeconomic studies have been conducted. According to the results of the ABC analysis, group A includes one drug (INN Ursodeoxycholic acid). According to the results of VEN analysis, it was proved that one drug (INN Prednizolone) belongs to category V (Vital). This study provides an opportunity to make administrative and managerial decisions in determining the pharmacotherapy of patients with alcoholic hepatitis to improve the use of drugs in hospitals.

show abstract

Section: Introductionmentioning

confidence: 99%

Interdisciplinary Pharmacoeconomic Research Concerning the Рharmacotherapy of Alcoholic Hepatitis in Conditions of Covid-19 Pandemic

Шаповалова

2023

SSPMPM

View full text Add to dashboard Cite

show abstract

Medications for alcohol‐use disorder and follow‐up after hospitalization for alcohol withdrawal: A multicenter study

Allaudeen,

Akwe,

Arundel

et al. 2024

Journal of Hospital Medicine

View full text Add to dashboard Cite

BackgroundAlcohol withdrawal is a common reason for admission to acute care hospitals. Prescription of medications for alcohol‐use disorder (AUD) and close outpatient follow‐up are commonly recommended, but few studies report their effects on postdischarge outcomes.ObjectivesThe objective of this study is to evaluate the effects of medications for AUD and follow‐up appointments on readmission and abstinence.MethodsThis retrospective cohort study evaluated veterans admitted for alcohol withdrawal to medical services at 19 Veteran Health Administration hospitals between October 1, 2018 and September 30, 2019. Factors associated with all‐cause 30‐day readmission and 6‐month abstinence were examined using logistic regression.ResultsOf the 594 patients included in this study, 296 (50.7%) were prescribed medications for AUD at discharge and 459 (78.5%) were discharged with follow‐up appointments, including 251 (42.8%) with a substance‐use clinic appointment, 191 (32.9%) with a substance‐use program appointment, and 73 (12.5%) discharged to a residential program. All‐cause 30‐day readmission occurred for 150 patients (25.5%) and 103 (17.8%) remained abstinent at 6 months. Medications for AUD and outpatient discharge appointments were not associated with readmission or abstinence. Discharge to residential treatment program was associated with reduced 30‐day readmission (adjusted odds ratio [AOR]: 0.39, 95% confidence interval [95% CI]: 0.18–0.82) and improved abstinence (AOR: 2.50, 95% CI: 1.33–4.73).ConclusionsReadmission and return to heavy drinking are common for patients discharged for alcohol withdrawal. Medications for AUD were not associated with improved outcomes. The only intervention at the time of discharge that improved outcomes was discharge to residential treatment program, which was associated with decreased readmission and improved abstinence.

show abstract

Impact of social vulnerability index on patients with alcohol-related liver disease

Jain,

Wellner,

Peng

et al. 2024

Alcohol

View full text Add to dashboard Cite

Alcohol use disorder treatment and outcomes among hospitalized adults with alcoholic hepatitis

Cited by 6 publications

References 35 publications

Interdisciplinary Pharmacoeconomic Research Concerning the Рharmacotherapy of Alcoholic Hepatitis in Conditions of Covid-19 Pandemic

Interdisciplinary Pharmacoeconomic Research Concerning the Рharmacotherapy of Alcoholic Hepatitis in Conditions of Covid-19 Pandemic

Medications for alcohol‐use disorder and follow‐up after hospitalization for alcohol withdrawal: A multicenter study

Impact of social vulnerability index on patients with alcohol-related liver disease

Contact Info

Product

Resources

About